Product Details

• Catalog Number: T0538
• Unit Size: 1×10⁶ cells / 1.0 ml
• Species: Human (Homo sapiens)
• Tissue: Heart
• Donor Information: Female, 33 years old, Caucasian, Ventricle
• Cell Type: Immortalized cardiomyocytes
• Growth Properties: Adherent, multipolar
• Expression Markers: GATA-4, ACTN2, ACTN3 and MYH2
• Biosafety Level: BSL-2
• Storage: Vapor phase of liquid nitrogen, or below -130°C
• Shipping: Shipped on dry ice
• Format: Cryopreserved frozen cells

Overview

Immortalized Human Cardiomyocytes – HPV E6/E7 have been derived from heart ventricles and modified using lentiviral transduction of HPV 16 E6/E7 genes. This enables indefinite proliferation while preserving key cardiomyocyte characteristics. These cells are ideal for cardiac research, including drug screening, electrophysiological studies, and disease modeling.

Key Features and Benefits

• Long-Term Viability: Immortalized for extended culture duration without senescence.
• Reproducibility: Provides consistent results across multiple experiments.
• Ideal for Cardiac Research: Supports studies on cardiac hypertrophy, electrophysiology, and cardiotoxicity.
• Optimized Growth Conditions: Adapted to specific media and extracellular matrices for enhanced viability.
• Adherent Growth Properties: Facilitates easy handling and maintenance in culture.

Culture & Handling Guidelines

Recommended Culture Conditions

• Coating: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) for optimal adhesion.
• Growth Medium: PriGrow I (TM001) supplemented with: 
  • 10% Fetal Bovine Serum (FBS)
  • 1% Penicillin/Streptomycin Solution (G255)
• Incubation Conditions: 37°C, 5% CO₂ humidified atmosphere
• Seeding Density: 10,000 – 20,000 cells/cm²
• Doubling Time: 18 – 27 hours

Thawing Protocol

1. Thaw cells quickly in a 37°C water bath (maximum 2 minutes). Keep the vial cap above the water level to avoid contamination.
2. Decontaminate the vial with 70% ethanol and transfer to a biosafety cabinet.
3. Add thawed cells to a sterile 15 mL conical tube containing 5 mL of pre-warmed complete growth medium.
4. Centrifuge at 125xg for 5-7 minutes.
5. Aspirate the supernatant and resuspend the pellet in fresh complete growth medium.
6. Seed cells in a pre-coated T25 flask and incubate under the recommended conditions.

Subculturing Guidelines

1. Aspirate the old medium and rinse cells with PBS.
2. Add 2-3 mL of pre-warmed 0.25% Trypsin-EDTA and incubate at 37°C until cells detach (2-10 minutes).
3. Neutralize Trypsin-EDTA by adding an equal volume of complete medium.
4. Centrifuge at 125xg for 5 minutes, aspirate the supernatant, and resuspend the pellet in fresh medium.
5. Seed cells into new culture vessels at the appropriate density.
6. Incubate under the recommended conditions and monitor for confluency.

Cryopreservation Guidelines

• Cryopreservation Medium: Use Cryopreservation Medium (TM024) or complete growth medium supplemented with 10% DMSO.
• Freezing Procedure: Freeze at a controlled rate (-1°C per minute) before transferring to liquid nitrogen storage.

Related Products

• Recombinant Human VEGF (121aa) (E. coli) – Z102115
• Recombinant Human Beta-NGF – Z101545
• Recombinant Human TGF Beta-1 (TGFB1) – Z101555
• Recombinant Human IGF1 (E. coli) – Z100385

Disclaimer

1. Material Transfer Agreement (MTA): Purchase of this item requires completion of an MTA.
2. Performance Verification: Test parameters provided in the Certificate of Analysis (CoA) were conducted under standardized conditions. Variations may occur under different culture conditions.
3. Research Use Only: All cell biology products are for research purposes ONLY and NOT for therapeutic/diagnostic applications. The company is not liable for unintended uses.
4. Warranty: The company guarantees cell viability for 30 days after shipment, provided storage and handling instructions are followed.
5. Accuracy of Information: Literature citations and descriptions are provided for informational purposes only and are not guaranteed for accuracy.

Reference

1. Kono, Ken, et al. “Development of selective cytotoxic viral vectors for concentration of undifferentiated cells in cardiomyocytes derived from human induced pluripotent stem cells.” Scientific reports 9.1 (2019): 3630.